- Home
- DDS vs IONS Comparison
DDS vs IONS Comparison
Compare DDS & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDS
- IONS
- Stock Information
- Founded
- DDS 1938
- IONS 1989
- Country
- DDS United States
- IONS United States
- Employees
- DDS N/A
- IONS N/A
- Industry
- DDS Department/Specialty Retail Stores
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- DDS Consumer Discretionary
- IONS Health Care
- Exchange
- DDS Nasdaq
- IONS Nasdaq
- Market Cap
- DDS 6.3B
- IONS 5.9B
- IPO Year
- DDS N/A
- IONS 1991
- Fundamental
- Price
- DDS $450.33
- IONS $43.59
- Analyst Decision
- DDS Sell
- IONS Buy
- Analyst Count
- DDS 2
- IONS 16
- Target Price
- DDS $310.00
- IONS $58.25
- AVG Volume (30 Days)
- DDS 139.1K
- IONS 1.9M
- Earning Date
- DDS 08-14-2025
- IONS 07-31-2025
- Dividend Yield
- DDS 5.78%
- IONS N/A
- EPS Growth
- DDS N/A
- IONS N/A
- EPS
- DDS 36.07
- IONS N/A
- Revenue
- DDS $6,564,393,000.00
- IONS $717,253,000.00
- Revenue This Year
- DDS N/A
- IONS $7.98
- Revenue Next Year
- DDS N/A
- IONS $16.09
- P/E Ratio
- DDS $12.47
- IONS N/A
- Revenue Growth
- DDS N/A
- IONS N/A
- 52 Week Low
- DDS $282.24
- IONS $23.95
- 52 Week High
- DDS $510.00
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- DDS 73.09
- IONS 83.14
- Support Level
- DDS $410.19
- IONS $39.37
- Resistance Level
- DDS $420.52
- IONS $40.61
- Average True Range (ATR)
- DDS 11.83
- IONS 1.34
- MACD
- DDS 3.45
- IONS 0.39
- Stochastic Oscillator
- DDS 96.83
- IONS 98.66
About DDS Dillard's Inc.
Dillard's Inc is an American fashion apparel, cosmetics, and home furnishings retailer. Its stores offer a large variety of merchandise and feature products from both national and exclusive brand sources. The company also operates a general contracting construction company, CDI Contractors. CDI Contractors' business includes constructing and remodelling stores for Dillards. The merchandise selections include exclusive brand merchandise such as Antonio Melani, Gianni Bini, Daniel Cremieux, Roundtree & Yorke, and private-label merchandise, among others. The company operates in two business segments; Retail Operations and Construction. The Retail Operations segment generates maximum revenue for the company.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.